Botulinum Toxin Vaccine
DOR BioPharma announces advances in mucosal vaccines for botulinum toxin
Published in Vaccine Weekly, May 10th, 2006
DOR is designing BT-VACC to be administered by the mucosal route, which offers significant advantages to the end user in terms of increased safety, lack of pain from injections, and ability to induce protective antibodies in the lung and intestines. These types of antibodies are associated with inactivation of botulinum toxins before they enter the body. These results are the first ever report of a combination of botulinum vaccine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-05-10)
More Articles from Vaccine Weekly
- Ebola Virus Vaccine
cAdVax-based bivalent Ebola vaccine induces immunity against Sudan and Zaire Ebola species - HIV/AIDS Vaccine
Robust HIV-specific immune responses were induced by DNA vaccine plus vaccinia virus boost - Tuberculosis Vaccine
Mycobacterium bovis BCG expressing SIV Gag protein induces immune responses - Vaccinia Virus Vaccine
Vaccinia virus mutated in envelope proteins A33R and B5R are immunogenic - Virology
Chimeric SIN/VEE viruses clear Venezuelan equine encephalitis virus from brain - Allergy & Immunology
IgG binding plant N-glycans were generated in rabbits but not in mice - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
